Company: IMNN
Filing Date: 2025-05-12
Form Type: 10-Q
Source: 0001641172-25-009572
Chunk: 123

Company: Imunon, Inc.
Filing Date: 2025-05-12
Form: 10-Q
Item: Part I, Item 8
Chunk 123
---
ability and classification of assets, carrying amounts or the amount and classification
of liabilities that may be required should the Company be unable to continue as a going concern.

    For the three months ended March 31, 

    (In thousands)  
    Change Increase (Decrease) 

    2025  
    2024  

    Operating Expenses: 

    Clinical Research 

    OVATION 
    $214  
    $287  
    $(73) 
     (25.4)%
  
    Vaccine 
     58  
     571  
     (513) 
     (89.8)%
  
    Other Clinical and regulatory 
     574  
     477  
     97  
     20.3%
  
    Subtotal 
     846  
     1,335  
     (489) 
     (36.6)%
  
    Non-Clinical R&D and CMC 

    OVATION 
     913  
     405  
     508  
     125.4%
  
    PlaCCine Vaccine 
     -  
     1,215  
     (1,215) 
     -%
  
    Manufacturing (CMC) 
     406  
     339  
     67  
     19.8%
  
    Subtotal 
     1,319  
     1,959  
     (640) 
     (32.7)%
  
    Research and development expenses 
     2,165  
     3,294  
     (1,129) 
     (34.3)%
  
    General and administrative expenses 
     1,980  
     1,717  
     263  
     15.3%
  
    Total operating expenses 
     4,145  
     5,011  
     (866) 
     (17.3)%
  
    Loss from operations 
    $(4,145) 
    $(5,011) 
    $(866) 
     (17.3)%

24

Research
and Development Expenses

Research
and development (“R&D”) expenses were $2.2 million in the first quarter of 2025 compared to $3.3 million in same period
of 2024.